{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:06:39Z","timestamp":1795089999146,"version":"4.10.2"},"reference-count":169,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Bone metastases represent a critical complication in oncology, frequently indicating advanced malignancy and substantially reducing patient quality of life. This review provides a comprehensive analysis of the complex interactions between tumor cells and the bone microenvironment, emphasizing the relevance of the \u201cseed and soil\u201d hypothesis, the RANK\/RANKL\/OPG signaling axis, and Wnt signaling pathways that collectively drive metastatic progression. The molecular and cellular mechanisms underlying the formation of osteolytic and osteoblastic lesions are examined in detail, with a particular focus on their implications for bone metastases associated with breast, prostate, lung, and other cancers. A central component of this review is the categorization of pathological biomarkers into four types: diagnostic, prognostic, predictive, and monitoring. We provide a comprehensive evaluation of circulating tumor cells (CTCs), bone turnover markers (such as TRACP-5b and CTX), advanced imaging biomarkers (including PET\/CT and MRI), and novel genomic signatures. These biomarkers offer valuable insights for early detection, enhanced risk stratification, and optimized therapeutic decision-making. Furthermore, emerging strategies in immunotherapy and bone-targeted treatments are discussed, highlighting the potential of biomarker-guided precision medicine to enhance personalized patient care. The distinctiveness of this review lies in its integrative approach, combining fundamental pathophysiological insights with the latest developments in biomarker discovery and therapeutic innovation. By synthesizing evidence across various cancer types and biomarker categories, we provide a cohesive framework aimed at advancing both the scientific understanding and clinical management of bone metastases.<\/jats:p>","DOI":"10.3390\/biomedicines13051160","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T04:21:23Z","timestamp":1747023683000},"page":"1160","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications"],"prefix":"10.3390","volume":"13","author":[{"given":"Youssef","family":"Elshimy","sequence":"first","affiliation":[{"name":"Department of Anatomy, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rahman","family":"Alkhatib","sequence":"additional","affiliation":[{"name":"Department of Anatomy, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Atassi","sequence":"additional","affiliation":[{"name":"Department of Anatomy, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9708-2111","authenticated-orcid":false,"given":"Khalid S.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Anatomy, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cam4.1932","article-title":"A Gene Expression Signature-Based Nomogram Model in Prediction of Breast Cancer Bone Metastases","volume":"8","author":"Zhao","year":"2019","journal-title":"Cancer Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hernandez, R.K., Wade, S.W., Reich, A., Pirolli, M., Liede, A., and Lyman, G.H. (2018). Incidence of Bone Metastases in Patients with Solid Tumors: Analysis of Oncology Electronic Medical Records in the United States. BMC Cancer, 18.","DOI":"10.1186\/s12885-017-3922-0"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2309499020915989","DOI":"10.1177\/2309499020915989","article-title":"Incidence, Prevalence, and Outcomes of Systemic Malignancy with Bone Metastases","volume":"28","author":"Jiang","year":"2020","journal-title":"J. Orthop. Surg. Hong Kong"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/1078-0432.CCR-18-2697","article-title":"Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis","volume":"25","author":"Rieunier","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10585-007-9099-1","article-title":"A Convenient Clinically Relevant Model of Human Breast Cancer Bone Metastasis","volume":"25","author":"Garcia","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_7","first-page":"4087","article-title":"Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer","volume":"23","author":"Zhang","year":"2017","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.3390\/curroncol30030199","article-title":"Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis","volume":"30","author":"Gelsomino","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9426","DOI":"10.1158\/0008-5472.CAN-05-0826","article-title":"A Blocking Antibody to Nerve Growth Factor Attenuates Skeletal Pain Induced by Prostate Tumor Cells Growing in Bone","volume":"65","author":"Halvorson","year":"2005","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/1078-0432.CCR-09-0982","article-title":"Targeting of Bone-Derived Insulin-like Growth Factor-II by a Human Neutralizing Antibody Suppresses the Growth of Prostate Cancer Cells in a Human Bone Environment","volume":"16","author":"Kimura","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yang, W., Pan, Q., Huang, F., Hu, H., and Shao, Z. (2022). Research Progress of Bone Metastases: From Disease Recognition to Clinical Practice. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1105745"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"016","DOI":"10.69613\/kqjwcv45","article-title":"A Review on Integration of Precision Medicine in Oncology Practice: Review Article","volume":"2","author":"Karimanal","year":"2024","journal-title":"J. Pharma Insights Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lee, S.-G. (2023). Molecular Target and Action Mechanism of Anti-Cancer Agents. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098259"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sharifi-Noghabi, H., Jahangiri-Tazehkand, S., Smirnov, P., Hon, C., Mammoliti, A., Nair, S.K., Mer, A.S., Ester, M., and Haibe-Kains, B. (2021). Drug Sensitivity Prediction from Cell Line-Based Pharmacogenomics Data: Guidelines for Developing Machine Learning Models. Brief. Bioinform., 22.","DOI":"10.1093\/bib\/bbab294"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40545-023-00590-9","article-title":"Delivering the Precision Oncology Paradigm: Reduced R&D Costs and Greater Return on Investment through a Companion Diagnostic Informed Precision Oncology Medicines Approach","volume":"16","author":"Henderson","year":"2023","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e000616","DOI":"10.1136\/esmoopen-2019-000616","article-title":"Precision Oncology in Urothelial Cancer","volume":"5","author":"Liow","year":"2020","journal-title":"ESMO Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2200246","DOI":"10.1200\/PO.22.00246","article-title":"Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non\u2013Small-Cell Lung Cancer","volume":"6","author":"Sadik","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jamaoncol.2020.7988","article-title":"Precision Medicine in Oncology\u2014Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations","volume":"7","author":"Yap","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/s41416-021-01329-6","article-title":"Bone Marrow Niches in the Regulation of Bone Metastasis","volume":"124","author":"Chen","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41413-020-00105-1","article-title":"Molecular Mechanisms and Clinical Management of Cancer Bone Metastasis","volume":"8","author":"Wang","year":"2020","journal-title":"Bone Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Haider, M.-T., Smit, D.J., and Taipaleenm\u00e4ki, H. (2020). The Endosteal Niche in Breast Cancer Bone Metastasis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00335"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Liu, Y., Chen, H., Chen, T., Qiu, G., and Han, Y. (2024). The Emerging Role of Osteoclasts in the Treatment of Bone Metastases: Rationale and Recent Clinical Evidence. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1445025"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1148\/radiol.2018172727","article-title":"Differentiation of Predominantly Osteoblastic and Osteolytic Spine Metastases by Using Susceptibility-Weighted MRI","volume":"290","author":"Adams","year":"2019","journal-title":"Radiology"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Yang, Z., Yue, Z., Ma, X., and Xu, Z. (2020). Calcium Homeostasis: A Potential Vicious Cycle of Bone Metastasis in Breast Cancers. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00293"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100610","DOI":"10.1016\/j.jbo.2024.100610","article-title":"Emerging Roles for Stromal Cells in Bone Metastasis","volume":"47","author":"Nyman","year":"2024","journal-title":"J. Bone Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liang, J., Liu, P., Wang, Q., Liu, L., and Zhao, H. (2022). The RANK\/RANKL\/OPG System and Tumor Bone Metastasis: Potential Mechanisms and Therapeutic Strategies. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1063815"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ming, J., Cronin, S.J.F., and Penninger, J.M. (2020). Targeting the RANKL\/RANK\/OPG Axis for Cancer Therapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01283"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ben-Ghedalia-Peled, N., and Vago, R. (2022). Wnt Signaling in the Development of Bone Metastasis. Cells, 11.","DOI":"10.3390\/cells11233934"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bonekey.2012.101","article-title":"Wnt and Wnt Inhibitors in Bone Metastasis","volume":"1","author":"Sottnik","year":"2012","journal-title":"BoneKEy Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00109-021-02159-y","article-title":"Targeting the Wnt Signaling Pathway for Breast Cancer Bone Metastasis Therapy","volume":"100","author":"Cui","year":"2022","journal-title":"J. Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/JLB.1AB0120-212RR","article-title":"Longitudinal Evaluation of Wnt Inhibitors and Comparison with Others Serum Osteoimmunological Biomarkers in Osteolytic Bone Metastasis","volume":"108","author":"Galliera","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Elaasser, B., Arakil, N., and Mohammad, K.S. (2024). Bridging the Gap in Understanding Bone Metastasis: A Multifaceted Perspective. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052846"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jcb.20735","article-title":"Role of Wnts in Prostate Cancer Bone Metastases","volume":"97","author":"Hall","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1021\/acsbiomaterials.9b00923","article-title":"Wnt\/\u03b2-Catenin Signaling Pathway Regulates Osteogenesis for Breast Cancer Bone Metastasis: Experiments in an In Vitro Nanoclay Scaffold Cancer Testbed","volume":"6","author":"Kar","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone Metastasis: Mechanisms, Therapies, and Biomarkers","volume":"101","author":"Coleman","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Xu, H., Lafage-Proust, M.-H., Bouazza, L., Geraci, S., Clezardin, P., Roche, B., Peyrin, F., and Langer, M. (2022). Impact of Anti-Angiogenic Treatment on Bone Vascularization in a Murine Model of Breast Cancer Bone Metastasis Using Synchrotron Radiation Micro-CT. Cancers, 14.","DOI":"10.3390\/cancers14143443"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Das, A., Barry, M.M., Ernst, C.A., Dahiya, R., Kim, M., Rosario, S.R., Lo, H.C., Yu, C., Dai, T., and Gugala, Z. (2024). Differential Bone Morphology and Hypoxia Activity in Skeletal Metastases of ER+ and ER\u2212 Breast Cancer. Commun. Biol., 7.","DOI":"10.1038\/s42003-024-07247-6"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3322\/caac.21768","article-title":"Radiotheranostics in Oncology: Making Precision Medicine Possible","volume":"73","author":"Aboagye","year":"2023","journal-title":"CA. Cancer J. Clin."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, S., Wu, W., Lin, X., Zhang, K.M., Wu, Q., Luo, M., and Zhou, J. (2023). Predictive and Prognostic Biomarkers of Bone Metastasis in Breast Cancer: Current Status and Future Directions. Cell Biosci., 13.","DOI":"10.1186\/s13578-023-01171-8"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ying, M., Mao, J., Sheng, L., Wu, H., Bai, G., Zhong, Z., and Pan, Z. (2023). Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction. J. Pers. Med., 13.","DOI":"10.3390\/jpm13050705"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hao, Y., Zhang, F., Ma, Y., Luo, Y., Zhang, Y., Yang, N., Liu, M., Liu, H., and Li, J. (2023). Potential Biomarkers for the Early Detection of Bone Metastases. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1188357"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wang, L., Fang, D., Xu, J., and Luo, R. (2020). Various Pathways of Zoledronic Acid against Osteoclasts and Bone Cancer Metastasis: A Brief Review. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07568-9"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tardoski, S., Ngo, J., Gineyts, E., Roux, J.-P., Cl\u00e9zardin, P., and Melodelima, D. (2015). Low-Intensity Continuous Ultrasound Triggers Effective Bisphosphonate Anticancer Activity in Breast Cancer. Sci. Rep., 5.","DOI":"10.1038\/srep16354"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/1878-0261.12997","article-title":"Liquid Biopsy: From Discovery to Clinical Implementation","volume":"15","author":"Pantel","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Iuliani, M., Simonetti, S., Ribelli, G., Napolitano, A., Pantano, F., Vincenzi, B., Tonini, G., and Santini, D. (2020). Current and Emerging Biomarkers Predicting Bone Metastasis Development. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00789"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Saxby, H., Mikropoulos, C., and Boussios, S. (2020). An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer. Diagnostics, 10.","DOI":"10.3390\/diagnostics10080549"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11795549241298541","DOI":"10.1177\/11795549241298541","article-title":"Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations","volume":"18","author":"AlDoughaim","year":"2024","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Louie, A.D., Huntington, K., Carlsen, L., Zhou, L., and El-Deiry, W.S. (2021). Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.747194"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jncc.2023.08.004","article-title":"Chinese Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2022 Edition)","volume":"3","author":"Duan","year":"2023","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.37349\/etat.2024.00278","article-title":"Predictive and Prognostic Biomarkers in Cancer: Towards the Precision Medicine Era","volume":"5","author":"Marletta","year":"2024","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.phrs.2019.04.030","article-title":"Osteopontin as a Multifaceted Driver of Bone Metastasis and Drug Resistance","volume":"144","author":"Pang","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Chai, X., Yinwang, E., Wang, Z., Wang, Z., Xue, Y., Li, B., Zhou, H., Zhang, W., Wang, S., and Zhang, Y. (2021). Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.692788"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40291-013-0077-9","article-title":"Prognostic and Predictive Biomarkers: Tools in Personalized Oncology","volume":"18","author":"Nalejska","year":"2014","journal-title":"Mol. Diagn. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Nakamura, S., Nagata, M., Nagaya, N., Ashizawa, T., Hirano, H., Lu, Y., Ide, H., and Horie, S. (2024). The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide. Cancers, 16.","DOI":"10.20944\/preprints202401.0336.v1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"20230117","DOI":"10.1259\/bjr.20230117","article-title":"Advances in the Study of Biomarkers Related to Bone Metastasis in Breast Cancer","volume":"96","author":"Xu","year":"2023","journal-title":"Br. J. Radiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41416-018-0367-4","article-title":"Circulating Tumour Cells and Their Association with Bone Metastases in Patients with Neuroendocrine Tumours","volume":"120","author":"Rizzo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/iju.15063","article-title":"Diagnostic and Prognostic Significance of Tartrate-Resistant Acid Phosphatase Type 5b in Newly Diagnosed Prostate Cancer with Bone Metastasis: A Real-World Multi-Institutional Study","volume":"30","author":"Yamamichi","year":"2023","journal-title":"Int. J. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bbcan.2014.09.001","article-title":"Bone Turnover Markers in Serum and Urine as Diagnostic, Prognostic and Monitoring Biomarkers of Bone Metastasis","volume":"1846","author":"Jung","year":"2014","journal-title":"Biochim. Biophys. Acta BBA Rev. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e12725","DOI":"10.1111\/ecc.12725","article-title":"The Value of Biomarkers in Bone Metastasis","volume":"26","author":"Brown","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00330-018-5682-x","article-title":"68Ga-PSMA-PET\/CT in Comparison with 18F-Fluoride-PET\/CT and Whole-Body MRI for the Detection of Bone Metastases in Patients with Prostate Cancer: A Prospective Diagnostic Accuracy Study","volume":"29","author":"Dyrberg","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.suronc.2013.01.002","article-title":"Comparison of 18 FDG PET-CT and Bone Scintigraphy for Detection of Bone Metastases in Breast Cancer Patients. A Meta-Analysis","volume":"22","author":"Rong","year":"2013","journal-title":"Surg. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Arimura, A., Sakai, K., Kaneshiro, K., Morisaki, T., Hayashi, S., Mizoguchi, K., Yamada, M., Kai, M., Ono, M., and Nishio, K. (2024). TP53 and\/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16061184"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1724600817753576","article-title":"Circulating Tumor DNA as Prognostic Markers for Late Stage NSCLC with Bone Metastasis","volume":"33","author":"Jia","year":"2018","journal-title":"Int. J. Biol. Markers"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/1724600819854452","article-title":"Use of Cell Free DNA as a Prognostic Biomarker in Non-Small Cell Lung Cancer Patients with Bone Metastasis","volume":"34","author":"Ye","year":"2019","journal-title":"Int. J. Biol. Markers"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Song, S., Zhu, Y., Zhang, X., Chen, S., and Liu, S. (2023). Prognostic Values of Long Noncoding RNA in Bone Metastasis of Prostate Cancer: A Systematic Review and Meta-Analysis. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1085464"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1634\/theoncologist.2010-0358","article-title":"Potential Prognostic Biomarkers for Bone Metastasis from Hepatocellular Carcinoma","volume":"16","author":"Xiang","year":"2011","journal-title":"Oncologist"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Maroni, P., Gomarasca, M., and Lombardi, G. (2023). Long Non-Coding RNAs in Bone Metastasis: Progresses and Perspectives as Potential Diagnostic and Prognostic Biomarkers. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1156494"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Coleman, R. (2022). Bone-Targeted Agents and Metastasis Prevention. Cancers, 14.","DOI":"10.3390\/cancers14153640"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00520-020-05355-7","article-title":"Management of Bone Metastasis with Intravenous Bisphosphonates in Breast Cancer: A Systematic Review and Meta-Analysis of Dosing Frequency","volume":"28","author":"Yang","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5489\/cuaj.117","article-title":"Management of Skeletal-Related Events in Patients with Advanced Prostate Cancer and Bone Metastases: Incorporating New Agents into Clinical Practice","volume":"6","author":"So","year":"2012","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_71","first-page":"189","article-title":"Multimodal Imaging Provides Insight into Targeted Therapy Response in Metastatic Prostate Cancer to the Bone","volume":"8","author":"Hoff","year":"2018","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Bai, R., Lv, Z., Xu, D., and Cui, J. (2020). Predictive Biomarkers for Cancer Immunotherapy with Immune Checkpoint Inhibitors. Biomark. Res., 8.","DOI":"10.1186\/s40364-020-00209-0"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Simonaggio, A., Epaillard, N., Pobel, C., Moreira, M., Oudard, S., and Vano, Y.-A. (2021). Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). Cancers, 13.","DOI":"10.3390\/cancers13020231"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Yin, X., Song, Y., Deng, W., Blake, N., Luo, X., and Meng, J. (2024). Potential Predictive Biomarkers in Antitumor Immunotherapy: Navigating the Future of Antitumor Treatment and Immune Checkpoint Inhibitor Efficacy. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1483454"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/1759-7714.13361","article-title":"Pathologic Complete Response to Preoperative Immunotherapy in a Lung Adenocarcinoma Patient with Bone Metastasis: A Case Report","volume":"11","author":"Tang","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-016-3741-z","article-title":"A novel gene expression signature for bone metastasis in breast carcinomas","volume":"156","author":"Halfwerk","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/path.5197","article-title":"Identification and Validation of DOCK4 as a Potential Biomarker for Risk of Bone Metastasis Development in Patients with Early Breast Cancer","volume":"247","author":"Westbrook","year":"2019","journal-title":"J. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"100374","DOI":"10.1016\/j.jbo.2021.100374","article-title":"A Predictive Biomarker Panel for Bone Metastases: Liquid Biopsy Approach","volume":"29","author":"Bhadresha","year":"2021","journal-title":"J. Bone Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"14864","DOI":"10.18632\/aging.205314","article-title":"Exosomal Hsa-miR-151a-3p and Hsa-miR-877-5p Are Potential Novel Biomarkers for Predicting Bone Metastasis in Lung Cancer","volume":"15","author":"Zhao","year":"2023","journal-title":"Aging"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/172460081002500209","article-title":"Identification of a Novel Biomarker Signature Associated with Risk for Bone Metastasis in Patients with Renal Cell Carcinoma","volume":"25","author":"Paule","year":"2010","journal-title":"Int. J. Biol. Markers"},{"key":"ref_81","first-page":"688","article-title":"Postoperative Expressions of TRACP5b and CA125 in Patients with Breast Cancer and Their Values for Monitoring Bone Metastasis","volume":"25","author":"Feng","year":"2020","journal-title":"J. BUON"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/1055-9965.EPI-04-0842","article-title":"Tartrate-Resistant Acid Phosphatase 5b Activity Is a Useful Bone Marker for Monitoring Bone Metastases in Breast Cancer Patients after Treatment","volume":"15","author":"Chung","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tranon.2016.12.001","article-title":"The Usefulness of Bone Biomarkers for Monitoring Treatment Disease: A Comparative Study in Osteolytic and Osteosclerotic Bone Metastasis Models","volume":"10","author":"Valencia","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-022-01396-6","article-title":"Circulating Biomarkers for Diagnosis and Therapeutic Monitoring in Bone Metastasis","volume":"41","author":"Song","year":"2023","journal-title":"J. Bone Miner. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., Thakare, R.P., Banday, S., Mishra, A.K., and Das, G. (2023). Next-Generation Sequencing Technology: Current Trends and Advancements. Biology, 12, Correct in Biology 2024, 13, 286. https:\/\/doi.org\/10.3390\/biology13050286.","DOI":"10.3390\/biology13050286"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e154943","DOI":"10.1172\/JCI154943","article-title":"Targeting Mutations in Cancer","volume":"132","author":"Waarts","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Martins, I., Ribeiro, I.P., Jorge, J., Gon\u00e7alves, A.C., Sarmento-Ribeiro, A.B., Melo, J.B., and Carreira, I.M. (2021). Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring. Genes, 12.","DOI":"10.3390\/genes12030349"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-023-01715-z","article-title":"Clinical Application and Detection Techniques of Liquid Biopsy in Gastric Cancer","volume":"22","author":"Ma","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e2100421","DOI":"10.1200\/GO.21.00421","article-title":"Clinical Benefit of Comprehensive Genomic Profiling for Advanced Cancers in India","volume":"8","author":"Mathew","year":"2022","journal-title":"JCO Glob. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00074","article-title":"Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study","volume":"2","author":"Chawla","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and Other Third-Generation EGFR TKI in EGFR-Mutant NSCLC Patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_92","first-page":"100775","article-title":"The Impact of the Multi-Disciplinary Molecular Tumour Board and Integrative next Generation Sequencing on Clinical Outcomes in Advanced Solid Tumours","volume":"36","author":"Lam","year":"2023","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3322\/caac.21600","article-title":"An Overview of Precision Oncology Basket and Umbrella Trials for Clinicians","volume":"70","author":"Park","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1672-0229(04)02021-2","article-title":"Application of Proteomics in the Study of Tumor Metastasis","volume":"2","author":"Cai","year":"2004","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-007-9109-4","article-title":"The Bone Microenvironment in Metastasis; What Is Special about Bone?","volume":"27","author":"Bussard","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/j.1582-4934.2010.01115.x","article-title":"Role of the Metastasis-Promoting Protein Osteopontin in the Tumour Microenvironment","volume":"14","author":"Anborgh","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"B\u0103dil\u0103, A.E., R\u0103dulescu, D.M., Niculescu, A.-G., Grumezescu, A.M., R\u0103dulescu, M., and R\u0103dulescu, A.R. (2021). Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review. Cancers, 13.","DOI":"10.3390\/cancers13164229"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/1541-7786.MCR-23-0310","article-title":"Mass Spectrometry\u2013Based Proteomics Identifies Serpin B9 as a Key Protein in Promoting Bone Metastases in Lung Cancer","volume":"22","author":"Huang","year":"2024","journal-title":"Mol. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1021\/acs.jproteome.4c00338","article-title":"Proteomics Analysis of Interactions between Drug-Resistant and Drug-Sensitive Cancer Cells: Comparative Studies of Monoculture and Coculture Cell Systems","volume":"23","author":"Peng","year":"2024","journal-title":"J. Proteome Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1158\/1078-0432.CCR-14-3378","article-title":"Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models","volume":"22","author":"Benito","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s12276-020-00504-8","article-title":"Glutamine Reliance in Cell Metabolism","volume":"52","author":"Yoo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered Metabolism in Cancer: Insights into Energy Pathways and Therapeutic Targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_103","first-page":"119","article-title":"Reexamining Cancer Metabolism: Lactate Production for Carcinogenesis Could Be the Purpose and Explanation of the Warburg Effect","volume":"38","author":"Brooks","year":"2017","journal-title":"Carcinogenesis"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","article-title":"Targeting Glutamine Metabolism as a Therapeutic Strategy for Cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Lu, J., Hu, D., Zhang, Y., Ma, C., Shen, L., and Shuai, B. (2023). Current Comprehensive Understanding of Denosumab (the RANKL Neutralizing Antibody) in the Treatment of Bone Metastasis of Malignant Tumors, Including Pharmacological Mechanism and Clinical Trials. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1133828"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s13018-021-02554-8","article-title":"Comparison of Denosumab and Zoledronic Acid for the Treatment of Solid Tumors and Multiple Myeloma with Bone Metastasis: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials","volume":"16","author":"Jiang","year":"2021","journal-title":"J. Orthop. Surg."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1158\/1078-0432.CCR-23-1801","article-title":"RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial","volume":"29","author":"Link","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Tumour-Agnostic Efficacy and Safety of Erdafitinib in Patients with Advanced Solid Tumours with Prespecified FGFR Alterations: RAGNAR Phase 2 Study Primary Analysis","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR Signaling Transduction Pathway and Targeted Therapies in Cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Zhu, Y., She, J., Sun, R., Yan, X., Huang, X., Wang, P., Li, B., Sun, X., Wang, C., and Jiang, K. (2024). Impact of Bone Metastasis on Prognosis in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1493773"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"17921","DOI":"10.1039\/C9RA02258A","article-title":"Metastasis Manners and the Underlying Mechanisms of ALK and ROS1 Rearrangement Lung Cancer and Current Possible Therapeutic Strategies","volume":"9","author":"Chang","year":"2019","journal-title":"RSC Adv."},{"key":"ref_113","first-page":"27","article-title":"Bisphosphonates in Oncology: Evidence for the Prevention of Skeletal Events in Patients with Bone Metastases","volume":"3","author":"Polascik","year":"2009","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1021\/acsami.8b16588","article-title":"Zoledronic Acid-Containing Nanoparticles With Minimum Premature Release Show Enhanced Activity Against Extraskeletal Tumor","volume":"11","author":"Li","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1021\/acs.langmuir.6b02228","article-title":"Bone-Targeted Mesoporous Silica Nanocarrier Anchored by Zoledronate for Cancer Bone Metastasis","volume":"32","author":"Sun","year":"2016","journal-title":"Langmuir ACS J. Surf. Colloids"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-Dose 177Lu-PSMA-617 Followed by Maintenance Pembrolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: An Open-Label, Dose-Expansion, Phase 1 Trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41416-019-0686-0","article-title":"A Model Combining Clinical and Genomic Factors to Predict Response to PD-1\/PD-L1 Blockade in Advanced Urothelial Carcinoma","volume":"122","author":"Nassar","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e081480","DOI":"10.1136\/bmjopen-2023-081480","article-title":"Clinical Variables Associated with Immune Checkpoint Inhibitor Outcomes in Patients with Metastatic Urothelial Carcinoma: A Multicentre Retrospective Cohort Study","volume":"14","author":"Labidi","year":"2024","journal-title":"BMJ Open"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/jbmr.4615","article-title":"Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice","volume":"37","author":"Arellano","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T Therapies in Multiple Myeloma: Unleashing the Future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1038\/s41467-024-51337-2","article-title":"CAR T-Cell-Mediated Delivery of Bispecific Innate Immune Cell Engagers for Neuroblastoma","volume":"15","author":"McIntyre","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s43018-020-00141-0","article-title":"Accelerating Precision Medicine in Metastatic Prostate Cancer","volume":"1","author":"Mateo","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00122","article-title":"Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study","volume":"2","author":"Mangat","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/jnci\/djz245","article-title":"The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design","volume":"112","author":"Flaherty","year":"2020","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ctrv.2015.12.008","article-title":"Clinical Trial Designs Incorporating Predictive Biomarkers","volume":"43","author":"Renfro","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone Health in Cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Faiella, E., Santucci, D., Calabrese, A., Russo, F., Vadal\u00e0, G., Zobel, B.B., Soda, P., Iannello, G., de Felice, C., and Denaro, V. (2022). Artificial Intelligence in Bone Metastases: An MRI and CT Imaging Review. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19031880"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid Biopsy in Cancer: Current Status, Challenges and Future Prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12943-023-01870-3","article-title":"Liquid Biopsy Techniques and Pancreatic Cancer: Diagnosis, Monitoring, and Evaluation","volume":"22","author":"Wang","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1007\/s00520-020-05357-5","article-title":"Real-World Use of Denosumab and Bisphosphonates in Patients with Solid Tumours and Bone Metastases in Germany","volume":"28","author":"Diel","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Hildenbrand, N., Thiele, W., Tripel, E., Renkawitz, T., Kermani, F., El-Fiqi, A., and Westhauser, F. (2024). Fe-Doped 45S5 Bioactive Glass Compositions Impair the Metabolic Activity and Proliferation of Metastatic Human Breast Cancer Cells in Vitro. Biomed. Mater., 19.","DOI":"10.1088\/1748-605X\/ad651c"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1272\/jnms.JNMS.2024_91-210","article-title":"Difficulties Nurses Report in Caring for Patients with Bone Metastases and Their Expectations after Participating in a Bone Metastasis Cancer Board: A Questionnaire Study","volume":"91","author":"Kitagawa","year":"2024","journal-title":"J. Nippon Med. Sch."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1007\/s00520-016-3154-x","article-title":"Burden of Symptoms Associated with Development of Metastatic Bone Disease in Patients with Breast Cancer","volume":"24","author":"Cleeland","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/13696998.2020.1864920","article-title":"The Burden of Skeletal-Related Events in Four Latin American Countries: Argentina, Brazil, Colombia, and Mexico","volume":"24","author":"Aziziyeh","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Knapp, B.J., Cittolin-Santos, G.F., Flanagan, M.E., Grandhi, N., Gao, F., Samson, P.P., Govindan, R., and Morgensztern, D. (2024). Incidence and Risk Factors for Bone Metastases at Presentation in Solid Tumors. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1392667"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Baldessari, C., Pipitone, S., Molinaro, E., Cerma, K., Fanelli, M., Nasso, C., Oltrecolli, M., Pirola, M., D\u2019Agostino, E., and Pugliese, G. (2023). Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications. Cancers, 15.","DOI":"10.3390\/cancers15051518"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e016022","DOI":"10.1136\/bmjopen-2017-016022","article-title":"Survival after Bone Metastasis by Primary Cancer Type: A Danish Population-Based Cohort Study","volume":"7","author":"Svensson","year":"2017","journal-title":"BMJ Open"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Song, X., Wei, C., and Li, X. (2022). The Signaling Pathways Associated With Breast Cancer Bone Metastasis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.855609"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"100337","DOI":"10.1016\/j.jbo.2020.100337","article-title":"Application of \u201cOmics\u201d Sciences to the Prediction of Bone Metastases from Breast Cancer: State of the Art","volume":"26","author":"Gentile","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrc.2017.126","article-title":"Genetic Insights into the Morass of Metastatic Heterogeneity","volume":"18","author":"Hunter","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Wood, S.L., and Brown, J.E. (2020). Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases. Cancers, 12.","DOI":"10.3390\/cancers12082109"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Aguilar-Mahecha, A., Kuzyk, M.A., Domanski, D., Borchers, C.H., and Basik, M. (2012). The Effect of Pre-Analytical Variability on the Measurement of MRM-MS-Based Mid- to High-Abundance Plasma Protein Biomarkers and a Panel of Cytokines. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038290"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrclinonc.2014.202","article-title":"Pragmatic Issues in Biomarker Evaluation for Targeted Therapies in Cancer","volume":"12","author":"Watson","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Drugan, T., and Leucu\u021ba, D. (2024). Evaluating Novel Biomarkers for Personalized Medicine. Diagnostics, 14.","DOI":"10.3390\/diagnostics14060587"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"100863","DOI":"10.18632\/oncotarget.19809","article-title":"Challenges and Future of Biomarker Tests in the Era of Precision Oncology: Can We Rely on Immunohistochemistry (IHC) or Fluorescence in Situ Hybridization (FISH) to Select the Optimal Patients for Matched Therapy?","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4143\/crt.2019.718","article-title":"PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-Offs","volume":"52","author":"Park","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/OP.23.00601","article-title":"Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Personalized Medicine in Cancer Care","volume":"20","author":"Tsimberidou","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Haider, M.-T., and Taipaleenm\u00e4ki, H. (2018). Targeting the Metastatic Bone Microenvironment by MicroRNAs. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00202"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/1568009615666150629102408","article-title":"Bone Metastasis-Related MicroRNAs: New Targets for Treatment?","volume":"15","author":"Zhao","year":"2015","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Dawalibi, A., Alosaimi, A.A., and Mohammad, K.S. (2024). Balancing the Scales: The Dual Role of Interleukins in Bone Metastatic Microenvironments. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158163"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1373\/clinchem.2009.127514","article-title":"Antibody-Based Protein Multiplex Platforms: Technical and Operational Challenges","volume":"56","author":"Ellington","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/1740774513497541","article-title":"Analytical and Clinical Evaluation of Biomarkers Assays: When Are Biomarkers Ready for Prime Time?","volume":"10","author":"Pennello","year":"2013","journal-title":"Clin. Trials Lond. Engl."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MOT.0000000000001135","article-title":"Urine CXCL10 as a Biomarker in Kidney Transplantation","volume":"29","author":"Schaub","year":"2024","journal-title":"Curr. Opin. Organ Transplant."},{"key":"ref_157","unstructured":"Hess, R., and Laaff, H. (2017). Biorepositories and Biomarker Development: Regulatory Challenges. Biomark. J., 3."},{"key":"ref_158","first-page":"S129","article-title":"Quality Assurance and Quality Control Highlight the Variability between and within Assay Methods","volume":"51","author":"Bundell","year":"2019","journal-title":"Pathology"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Andreoletti, M., Haller, L., Vayena, E., and Blasimme, A. (2024). Mapping the Ethical Landscape of Digital Biomarkers: A Scoping Review. PLOS Digit. Health, 3.","DOI":"10.1371\/journal.pdig.0000519"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/WNL.0000000000001451","article-title":"Ethics of Genetic and Biomarker Test Disclosures in Neurodegenerative Disease Prevention Trials","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"25","DOI":"10.18063\/APM.2016.01.002","article-title":"Collaboration for Success: The Value of Strategic Collaborations for Precision Medicine and Biomarker Development","volume":"1","author":"Landeck","year":"2016","journal-title":"Adv. Precis. Med."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Chapman, C.R., Mehta, K.S., Parent, B., and Caplan, A.L. (2019). Genetic Discrimination: Emerging Ethical Challenges in the Context of Advancing Technology. J. Law Biosci., 7.","DOI":"10.1093\/jlb\/lsz016"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMp1404776","article-title":"GINA, Genetic Discrimination, and Genomic Medicine","volume":"372","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1017\/pcm.2024.3","article-title":"Ethical Frameworks of Informed Consent in the Age of Pediatric Precision Medicine","volume":"2","author":"Chen","year":"2024","journal-title":"Camb. Prisms Precis. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.7326\/M22-0743","article-title":"Ethical Considerations in Precision Medicine and Genetic Testing in Internal Medicine Practice: A Position Paper From the American College of Physicians","volume":"175","author":"Lehmann","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Baynam, G., Gomez, R., and Jain, R. (2024). Stigma Associated with Genetic Testing for Rare Diseases\u2014Causes and Recommendations. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1335768"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Ioannou, K.I., Constantinidou, A., and Chatzittofis, A. (2024). Genetic Testing in Psychiatry, the Perceptions of Healthcare Workers and Patients: A Mini Review. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1466585"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.3390\/curroncol31120592","article-title":"Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer","volume":"31","author":"Moffitt","year":"2024","journal-title":"Curr. Oncol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/5\/1160\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:30:28Z","timestamp":1760031028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/5\/1160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":169,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["biomedicines13051160"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13051160","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]}}}